As this year’s American Society of Clinical Oncology meeting draws to a close, take a break from your flight, train ride, or Twitter binge for a look at who’s leaving Chicago with a skip in their step and who might be dragging their feet all the way home.
The whole CAR-T cohort. Bluebird Bio stoked hopes that CAR-T will be more than a one-trick cell therapy with promising early data in multiple myeloma. A virtually unknown Chinese entrant, vividly named Nanjing Legend Biotech, came through with intriguing results of its own. And even the beleaguered Juno Therapeutics had good news to report in the form of positive results in lymphoma. The read-through: Hot-wiring cells to fight cancer is difficult, but scientists are gradually wrapping their heads around the idea. CAR-T sentiment is nowhere near 2014’s hysteria, but it’s on the mend after hitting a nadir last summer.